Investors

Press Releases

Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.

Select Year
Search …

Found 351 Results

Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

October 16, 2019

Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

September 12, 2019

Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

September 11, 2019

Palatin Technologies To Present At Canaccord Genuity’s 39th Annual Growth Conference

August 6, 2019

Palatin Technologies Provides Mid-Calendar Year Corporate Update

July 1, 2019

FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)

June 21, 2019

Palatin Technologies Granted FDA Orphan Drug Designation — PL-8177 for the Treatment of Non-Infectious Uveitis

June 6, 2019

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

May 9, 2019

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

May 3, 2019

Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases

April 4, 2019

Newer

Page 18 of 36

Older